Clinical-stage biopharmaceuticals
Redefining What's Possible in Medicine
We develop novel therapeutics that address unmet needs — driven by rigorous science and an unwavering commitment to patients.
Our mission
Science with purpose. Medicine with heart.
At Neologicals, we believe the most important breakthroughs happen at the intersection of bold science and deep human empathy. We build programs around mechanisms that others have overlooked — and we build teams around people who refuse to accept the status quo.
Every program we advance is a commitment: to the patients waiting, the partners investing, and the science that makes it possible.
Pipeline highlights
Programs built to matter
Our pipeline spans three therapeutic areas with a shared focus: novel mechanisms, validated targets, and a clear path to patients.
NG-101
Solid tumors — KRAS-mutant
A first-in-class small molecule targeting a novel allosteric site on mutant KRAS, designed to overcome resistance mechanisms seen with existing inhibitors.
Learn moreNG-204
ALS — TDP-43 pathology
A RNA-targeting therapeutic designed to restore TDP-43 function in motor neurons, addressing a root cause of ALS progression.
Learn moreNG-312
Lysosomal storage disorder
An enzyme replacement therapy with enhanced CNS penetration, targeting a rare pediatric lysosomal disorder with no approved treatment.
Learn moreNG-418
Hematologic malignancies
A bispecific antibody engaging T cells against a novel hematologic target, with early clinical signals showing durable responses.
Learn moreWhy Neologicals
What sets us apart
Novel mechanisms, not incremental science
We don't follow the crowd. Our scientific platform is built to identify and validate targets that others have dismissed — giving us a first-mover advantage in mechanisms that could redefine treatment paradigms.
Patient outcomes drive every decision
From target selection to trial design, we ask one question first: does this help patients? Our patient-first framework shapes how we prioritize programs, design studies, and measure success.
A team that has done this before
Our leadership team has collectively advanced over 20 drug candidates through clinical development, with multiple FDA approvals and successful exits. We know what it takes — and we've built the team to do it again.
Strategic partnerships that accelerate
We partner selectively with institutions, CROs, and co-development partners who share our standards. Our network spans leading academic medical centers, global clinical sites, and top-tier investors.
For investors & partners
Built for the Long Game
We're building Neologicals to last — with a pipeline designed for durability, a team built for execution, and a culture that attracts the best scientists and operators in the industry. If you're looking for a partner who thinks in decades, not quarters, we'd like to talk.